Jean-Marc Gombert

Title: Innovations by Jean-Marc Gombert in Preventing Ischemia Reperfusion Injury

Introduction

Jean-Marc Gombert is a notable inventor based in Poitiers, France. He has made significant contributions to the field of medical research, particularly in understanding and preventing ischemia reperfusion injury (IRI). His work focuses on the role of interleukin-33 (IL-33) in tissue injury and the innate immune response.

Latest Patents

Jean-Marc Gombert holds a patent titled "Methods for preventing ischemia reperfusion injury in an organ with antibody antagonists of IL-33." This patent addresses the inflammation associated with IRI, which is characterized by leukocyte infiltration and renal tubular injury. The research identifies IL-33 as a critical factor in initiating tissue injury and amplifying the immune response during kidney IRI in experimental models. The findings suggest that antagonists of IL-33 can be utilized to prevent IRI, thereby preserving renal function and reducing injury.

Career Highlights

Throughout his career, Jean-Marc Gombert has worked with esteemed institutions such as the National Institute of Health and Medical Research (Institut National De La Santé Et De La Recherche Médicale) and the University Hospital of Poitiers (Centre Hospitalier Universitaire De Poitiers). His research has contributed to a deeper understanding of the mechanisms underlying ischemia reperfusion injury and potential therapeutic interventions.

Collaborations

Jean-Marc has collaborated with notable colleagues, including André Herbelin and Maroua Ferhat. Their combined expertise has further advanced the research in this critical area of medical science.

Conclusion

Jean-Marc Gombert's innovative work in the field of ischemia reperfusion injury highlights the importance of understanding immune responses in organ injury. His contributions through patents and collaborations continue to pave the way for potential therapeutic advancements in medical research.